Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of software and
consulting services for pharmaceutical R&D and environmental toxicology,
announced that it expects to file its annual report on Form 10-K for the
2014 fiscal year ended August 31, 2014, with the U.S. Securities and
Exchange Commission by Monday, December 1, 2014. Dr. Ted Grasela,
president, and Walt Woltosz, chairman and CEO, will host a conference
call to discuss the Company’s performance on Tuesday, November 25, 2014,
at 1:15 p.m. PST / 4:15 p.m. EST.
The conference call will be webcast live and may be joined by
registering at https://attendee.gotowebinar.com/register/1195372911604984578.
Upon registering, you will receive a confirmation e-mail with
instructions for joining the call. Please dial in five to ten minutes
prior to the scheduled start time.
About Simulations Plus, Inc.
Simulations Plus, Inc., is a premier developer of groundbreaking drug
discovery and development simulation and modeling software and
consulting services, which is licensed to and used in the conduct of
drug research by major pharmaceutical, biotechnology, agrochemical, and
food industry companies worldwide. Simulations Plus recently acquired Cognigen,
Inc. of Buffalo, NY, adding top-quality clinical trial data analysis
to our offerings and more than doubling our staff from 30 to 65, adding
nearly 50% to revenues, and increasing earnings in the coming fiscal
year that began September 1. Simulations Plus is headquartered in
Southern California and trades on the NASDAQ Capital Market under the
symbol “SLP.” For more information, visit our Web site at www.simulations-plus.com.
Copyright Business Wire 2014